GLP-1 Marketing Guidelines: One Map of the US Rules

There is no single set of GLP-1 marketing guidelines in the US. A telehealth ad answers to several layers at once. The FTC governs claims, testimonials and pricing. The FDA governs how compounded drugs are described. State medical boards govern their licensees’ advertising. Platforms add their own gates. This page maps each ad element to the rule it touches.

Rules and Meta policy checked on November 2, 2026.

Which agency covers which part of the ad

The FTC has primary responsibility for claims in advertising, and the FDA has primary responsibility for claims in labeling, according to the FTC’s own guidance. The agencies share jurisdiction and coordinate. A telehealth brand’s pages can fall under both, so the layers below stack instead of replacing each other.

The FTC guidance describes itself as business guidance without the force of law, and it says it is not a safe harbor. The same page explains that the agency reads each ad as a whole.

The ad-element matrix

Each row below is one part of a GLP-1 ad or funnel, the rule that touches it, what the primary text says, and where this site goes deeper.

FTC claims and substantiation

The FTC reduces its advertising law to two principles. Advertising must be truthful and not misleading, and advertisers must have adequate substantiation for all objective claims, express or implied, before disseminating the ad. The guidance covers social media, influencer marketing and indirect promotion through intermediaries.

Two points matter most for GLP-1 funnels. The FTC judges the net impression of the whole ad, including text, product name, charts and images, so a compliant headline can sit next to a misleading image. And a disclosure cannot directly contradict a claim. The guidance says “Results not typical” does not cure a dramatic testimonial.

The FTC also states, “Anyone participating in deceptive marketing is potentially liable under FTC law.” The guidance cites court decisions applying the substantiation standard to weight-loss claims. The misleading ad claims page goes deeper on the FDA side.

Testimonials, endorsements and reviews

The Endorsement Guides say consumer endorsements are not competent and reliable scientific evidence (16 CFR 255.2(a)). An advertiser still needs real substantiation behind what the testimonial implies. If an endorser’s result is not what consumers generally achieve, 255.2(b) says the ad should disclose the generally expected result. In its weight-loss example, a before-and-after photo with “I lost 50 pounds” is likely to read as representative.

Part 465, effective October 21, 2024, adds rules with their own section numbers:

• 465.2 covers fake or false reviews and testimonials, including ones that misrepresent that the reviewer used the product.
• 465.4 bars compensation conditioned on a review expressing a particular sentiment.
• 465.5 requires officers and managers to disclose their relationship to the business.
• 465.7 covers review suppression.

For creators, see GLP-1 influencer rules and celebrity GLP-1 ads.

Pricing and what the price covers

The FTC’s NextMed matter is the clearest GLP-1 telehealth example of a pricing claim. The FTC alleged that NextMed misrepresented that its membership price included the cost of a GLP-1 drug and the other services needed to get a prescription. It also alleged unsubstantiated claims that participants lost on average 53 pounds and 23% of body weight.

The proposed order barred misrepresenting that a telehealth service price includes consultations, lab work or a drug. It also barred misrepresenting the total cost to obtain a product or service. On December 3, 2025, the FTC announced that the Commission had voted 2-0 to approve the final order, which requires $150,000 in payments. The complaint’s charges are allegations, and the consent order settles them.

FDA lines on compounded drugs

FDA’s telehealth page, current as of June 15, 2026, reminds telehealth companies not to market compounded GLP-1 drugs to consumers with false or misleading claims. It lists five examples:

• Branding on a website that falsely or misleadingly implies the telehealth company is the compounder.
• Calling a compounded drug a generic version of, or the same as, an FDA-approved drug.
• Claiming FDA approval or a safety and effectiveness review.
• Calling it clinically proven to match the approved drug’s result.
• Claiming it comes from an FDA-approved or FDA-licensed pharmacy or outsourcing facility, since FDA does not approve or license any facility.

See misleading ad claims for the warning-letter detail.

State medical board advertising rules

State board advertising rules bind licensees, and each state writes its own text. Texas shows the shape. Under 22 TAC 164.3, in the version effective January 9, 2025, a physician advertisement is deemed false, deceptive or misleading if it carries a testimonial without a credentials disclaimer and a compensation disclosure, or fails to identify models or actors as such. It is also deemed misleading with untruthful fee claims, including free-service claims where a third party is billed.

The rule sits in the Texas Medical Board’s chapter on physician advertising, so it reaches licensed physicians, not every advertiser. Texas is one example, not a template for other states.

Platform gates, briefly

Platform policy is a separate layer from law, and a clean ad can still be blocked. Meta’s Drugs and Pharmaceuticals standard says advertisers do not need written authorization to run ads that “promote telehealth services generally.” Ads that promote prescription drugs need active LegitScript certification and Meta authorization.

Related pages cover Meta’s weight-loss policy, Google’s healthcare policy, LegitScript by platform, LegitScript and health-data restrictions.

Who is on the hook

Liability under the Endorsement Guides reaches more than the brand. Each row below is drawn from 16 CFR 255.1, 255.4 and 255.5 and the FTC guidance.

The FTC guidance cites actions against ad agencies, distributors and an affiliate advertising network among its examples.

What this means for your campaigns

The rules above translate into a short working routine:

1. Keep a substantiation file for each objective claim, written before the ad runs.
2. Review the ad and the landing page together, since the net impression is what counts.
3. Give affiliates and influencers approved claims and disclosure wording, then monitor what they publish, as 255.1(d) describes. See monitoring affiliate ads.
4. Re-confirm an expert or celebrity endorser’s views at reasonable intervals (255.1(b)).
5. Keep dated copies of approved creative, plus the version that actually ran.
6. Check compounded-drug wording against the practices FDA’s reminders list.

For the commercial side of the same campaigns, read the GLP-1 marketing strategy and how to advertise GLP-1 pages.

FAQ

Can telehealth brands use patient testimonials in ads?

Yes, if they are genuine and the ad can back the implied claim. Under 255.2, the advertiser needs substantiation for what the testimonial implies, and unrepresentative results call for a disclosure of generally expected results. Part 465 bars fake testimonials.

Can an ad say a compounded drug is the same as Ozempic?

FDA’s reminders list describing a compounded drug as a generic version of, or the same as, an FDA-approved drug as a false or misleading practice. The agency says generics are approved before marketing and compounded drugs are not.

Are affiliates responsible for GLP-1 advertising claims?

Potentially, and so is the brand. Section 255.1 says advertisers can be liable for endorsers’ statements, and endorsers can be liable for their own. The FTC guidance cites an action against an affiliate advertising network.

Does a disclaimer fix a misleading claim?

No. The guidance says a disclosure cannot directly contradict a claim, and it says “Results not typical” does not cure a dramatic testimonial.

Reaching the next customers

We run GLP-1 and telehealth traffic at scale with platform approvals on every network we buy. If you want to grow your brand’s customer base through Meta, Outbrain, TikTok, our own comparison sites and an affiliate network we manage, book a call.

Primary-source link kit

All pages accessed November 2, 2026.